Replimune Group (REPL) Expected to Announce Quarterly Earnings on Thursday

Replimune Group (NASDAQ:REPL) is expected to be releasing its Q4 2025 earnings data before the market opens on Thursday, May 15th. Analysts expect Replimune Group to post earnings of ($0.75) per share for the quarter.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Replimune Group Stock Down 5.7%

Shares of NASDAQ:REPL opened at $7.41 on Wednesday. The company has a market capitalization of $570.68 million, a PE ratio of -2.41 and a beta of 0.68. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The firm has a 50 day simple moving average of $9.27 and a 200-day simple moving average of $11.45.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on REPL. HC Wainwright upped their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, BMO Capital Markets increased their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Replimune Group currently has a consensus rating of “Buy” and a consensus price target of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.